Advertisement

Search Results

Advertisement



Your search for all items matches 608 pages

Showing 351 - 400


prostate cancer

A. Oliver Sartor, MD, on Results of the ALSYMPCA Trial for Castration-Resistant Prostate Cancer

A. Oliver Sartor, MD, of Tulane University School of Medicine, discusses the latest results of a clinical trial on radium-223 dichloride and the improvement in overall survival of men with advanced prostate cancer (Abstracts 2510, 2530).

head and neck cancer
prostate cancer

Bruce Minsky, MD, on Clinical Trial Results: The ASCENDE-RT Trial and a Multicenter Study on Prostate Cancer

Bruce Minsky, MD, of MD Anderson Cancer Center, discusses two important papers: results from a prospective trial on quality-of-life outcomes for low-risk HPV-associated oropharyngeal squamous cell carcinoma, and a prostate cancer radiation therapy study (Abstracts 3, 4).

prostate cancer

Anthony Zietman, MD, on Accelerating Treatment: RTOG 0415 Study on Prostate Cancer

Anthony Zietman, MD, of Massachusetts General Hospital, discusses the practice-changing results from a study comparing fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).

prostate cancer

Anthony Zietman, MD, on Hormonal Therapy and Salvage Radiation: Results of RTOG 9601

Anthony Zietman, MD, of Massachusetts General Hospital, discusses his perspective on the study of bicalutamide during and after radiotherapy in patients following radical prostatectomy and a biochemical relapse (Abstract LBA5).

prostate cancer

Howard M. Sandler, MD, on Prostate Cancer: Results of NRG Oncology/RTOG 9601

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses how adding 24 months of daily antiandrogen therapy during and after radiotherapy was shown to significantly improve long-term overall survival following prostate cancer recurrence after a radical prostatectomy (Abstract LBA5).

prostate cancer

James B. Yu, MD, on RTOG 0415: Fractionation Schedules in Patients With Low-Risk Prostate Cancer

James B. Yu, MD, of Yale School of Medicine, summarizes the plenary lecture on results from the NRG Oncology/phase III study comparing two fractionation schedules for low-risk prostate cancer (Abstract LBA6).

prostate cancer

Howard M. Sandler, MD, on Prostate Cancer: Results From RTOG 0415

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses this phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).

prostate cancer

Christopher Brian Allard, MD, on Prostate Cancer Risk and Regular Aspirin Use

Christopher Brian Allard, MD, of Brigham & Women's Hospital, reports on results of the Physicians’ Health Study, which showed that regular aspirin use decreased the risk of lethal prostate cancer in a cohort of American doctors (Abstract 306).

prostate cancer

Maha Hussain, MD, on Prostate Cancer: Keynote Lecture

Maha Hussain, MD, of the University of Michigan, gives her expert perspective on changes in the treatment of hormone-naive disease.

prostate cancer

W. Robert Lee, MD, on Prostate Cancer: Results of the NRG Oncology RTOG 0415 Study

W. Robert Lee, MD, of Duke University, discusses this phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract 1).

prostate cancer

Paul L. Nguyen, MD, on Prostate Cancer: Results of the NRG Oncology/RTOG 9601 Study

Paul L. Nguyen, MD, of Dana-Farber Cancer Institute, discusses this phase III trial in which prostate cancer patients were given antiandrogen therapy with bicalutamide during and after salvage radiation therapy following radical prostatectomy and an elevated PSA (Abstract 3).

prostate cancer

Fred Saad, MD, on Prostate Cancer: The Year in Review (French Language Version)

Fred Saad, MD, of the University of Montreal, summarizes in French his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease.

prostate cancer

Fred Saad, MD, on Prostate Cancer: The Year in Review

Fred Saad, MD, of the University of Montreal, summarizes his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease. To see the French language version of this video, click here.

prostate cancer

David P. Dearnaley, MD, on Prostate Cancer: Results from the CHHiP Trial

David P. Dearnaley, MD, of The Royal Marsden NHS Foundation Trust, discusses the comparison, in this study, of hypofractionated high-dose IMRT schedules for prostate cancer (Abstract 2).

prostate cancer

A. Oliver Sartor, MD, on Advanced Prostate Cancer: Predicting Treatment Resistance

A. Oliver Sartor, MD, of Tulane Cancer Center, discusses this study investigating circulating tumor cell characteristics to predict resistance to androgen deprivation therapies in patients with advanced prostate cancer (Abstract 163).

prostate cancer

DNA Damage and Repair Pathway Signature May Be Associated With Prognosis After Prostatectomy in High-Risk Prostate Cancer

In a study reported in JAMA Oncology, Evans et al identified a DNA damage and repair pathway gene signature that was significantly associated with outcomes after prostatectomy for high-risk prostate cancer independent of standard clinicopathologic factors. Study Details The study involved 1,090...

palliative care
prostate cancer

GU Symposium 2016: Even After Antiandrogen Therapy, Docetaxel Remains Useful in Prostate Cancer

A study presented at the 2016 Genitourinary Cancers Symposium showed that 40% of patients with metastatic castration-resistant prostate cancer treated with docetaxel following abiraterone (Zytiga) had at least a 50% reduction in prostate-specific antigen (PSA), demonstrating the activity of...

prostate cancer

GU Symposium 2016: New Blood Test Technology Shows Promise for Guiding Prostate Cancer Treatment Decisions

An early study suggests that an experimental blood test may help guide individualized decisions on the most appropriate treatments for patients with prostate cancer. The new noninvasive “liquid biopsy” scans the entire landscape of different kinds of cancer cells in blood and analyzes...

solid tumors
prostate cancer

GU Symposium 2016: Regular Aspirin Use May Reduce Risk of Dying From Prostate Cancer

A large observational study has found that men who take aspirin regularly may have a lower risk of dying from prostate cancer. Men who took aspirin regularly after their prostate cancer diagnosis were less likely to die from the disease. However, aspirin did not affect the overall incidence of...

prostate cancer

David Penson, MD, MPH, Receives $2 Million Research Award to Study Prostate Cancer  

David Penson, MD, MPH, Professor of Urologic Surgery, Vanderbilt University Medical Center, Nashville, has received a $2 million research award from the Patient-Centered Outcomes Research Institute to study localized prostate cancer. Dr. Penson is also Director of the Vanderbilt Center for Surgical ...

prostate cancer

California Stem Cell Agency Awards More than $40 Million in New Research Grants, including Funds for Prostate Cancer Research

The California Institute for Regenerative Medicine recently announced approval by the agency’s governing Board, the Independent Citizens Oversight Committee, of $40 million in funding for researchers at 10 institutions as part of its Early Translational IV Research awards. Among the institutions...

prostate cancer

Drew Pinsky, MD, Elected to Prostate Cancer Foundation Board of Directors

The Prostate Cancer Foundation has announced that Drew Pinsky, MD, has been elected to the Foundation’s Board of Directors. Dr. Pinsky, a cancer survivor, is a Practicing Physician and a Member of the Staff of Huntington Memorial Hospital in Pasadena, California.  He is also Assistant Clinical...

prostate cancer

Peter Carroll, MD, MPH, Receives Grant for Early Detection of Prostate Cancer

The ZERO Cancer Research Fund has awarded the Jim Lafferty Memorial Research Grant in the amount of $45,000 to Peter Carroll, MD, MPH, of the University of California San Francisco, for the purpose of researching new and improved methods for early detection of prostate cancer. The grant is part of...

prostate cancer
issues in oncology

Swedish Screening Model Improves Performance of Prostate Cancer Screening vs PSA Alone in Men Aged 50–69 Years

In a Swedish study reported in The Lancet Oncology (Stockholm 3 study), Grönberg et al found that a screening model including prostate-specific antigen (PSA) and other plasma protein markers, genetic polymorphisms, and clinical variables improved the accuracy of detecting prostate cancer with...

prostate cancer
issues in oncology

New ‘Condensed’ Grading System Shown to Be Accurate for Predicting Prostate Cancer Outcomes

Using information gleaned from more than 20,000 men, researchers at Johns Hopkins have affirmed the value of their alternative system for assessing the likelihood of growth and spread of prostate cancer. The new grading system, they said, is not only easier to use and understand, but also more...

prostate cancer
issues in oncology

Repeating Abnormal PSA Tests Reduces Number of Unnecessary Biopsies

For more than 20 years, the prostate-specific antigen (PSA) test has been used to help screen for prostate cancer. However, in recent years, some task forces have called for this blood test to be abandoned because it leads to many unnecessary biopsies. Now, a new study from The Ottawa Hospital and...

issues in oncology
prostate cancer
issues in oncology

Decreased Prostate-Specific Antigen Screening and Rate of Diagnosis in Early-Stage Prostate Cancer

Recent data indicated that the rates of prostate-specific antigen (PSA) screening and diagnosis of early-stage prostate cancer have decreased since a 2012 U.S. Preventive Services Task Force (USPSTF) statement (released in October 2011) gave a grade D recommendation against PSA screening for all...

palliative care
prostate cancer

Study Shows Abiraterone Acetate Is Useful Even in the Most Aggressive Prostate Cancers

In 1,048 prostate cancer patients previously treated with docetaxel, and 996 metastatic, castration-resistant patients, treatment with the androgen-lowering drug abiraterone acetate (Zytiga) led to longer overall disease control, even when a very high Gleason score indicated especially aggressive...

prostate cancer
issues in oncology
issues in oncology

Majority of Men Who Forgo Aggressive Treatment for Prostate Cancer Are Not Monitored Appropriately

An increasing number of men diagnosed with low-risk prostate cancer are opting for active surveillance rather than aggressive treatment to avoid the debilitating potential side effects of surgery and radiation, such as erectile and urinary dysfunction. However, a new study by University of...

prostate cancer
issues in oncology

Meta-Analysis Indicates Noninferiority of Overall Survival With Intermittent vs Continuous Androgen-Deprivation Therapy in Prostate Cancer

In a meta-analysis reported in JAMA Oncology, Magnan et al found that intermittent androgen-deprivation therapy was noninferior to continuous androgen-deprivation therapy with respect to overall survival in patients with prostate cancer. Study Details A literature review identified 22 articles...

issues in oncology
prostate cancer

Vigorous Exercise and Healthy Habits May Dramatically Reduce Chance of Lethal Prostate Cancer for Men Over 60

A study that tracked tens of thousands of middle-aged and older men for more than 20 years has found that vigorous exercise and other healthy lifestyle habits may cut their chances of developing a lethal type of prostate cancer by up to 68%. While most prostate cancers are clinically indolent, a...

palliative care
issues in oncology
prostate cancer

Two Studies Find Protein May Inhibit Prostate Cancer Bone Metastasis

Scientists from Lawrence Livermore National Laboratory (LLNL), in collaboration with researchers from University of California Merced and Davis, have found that a secreted protein predominantly expressed in bone inhibits prostate cancer metastasis to bone. Their research was published recently by...

prostate cancer
supportive care
integrative oncology

Yoga Helps Maintain Quality of Life, May Lessen Side Effects in Men Undergoing Prostate Cancer Treatment

Men with prostate cancer who are undergoing radiation therapy can benefit from yoga, researchers at the Perelman School of Medicine at the University of Pennsylvania reported at the Society for Integrative Oncology’s 12th International Conference. The new, first-of-its-kind study, led...

prostate cancer

PARP Inhibitor Olaparib Produces High Response Rate in Metastatic Prostate Cancer With DNA Repair Defects

In a phase II trial reported in The New England Journal of Medicine, Mateo et al found that the PARP inhibitor olaparib (Lynparza) produced a high response rate in patients with previously treated metastatic castration-resistant prostate cancer with tumors exhibiting defects in DNA repair genes....

prostate cancer
cost of care

Study Shows Wide Variation in Costs to Treat Low-Risk Prostate Cancer

University of California, Los Angeles (UCLA) researchers have described costs across the entire care process for low-risk prostate cancer—from the time a patient checks in for his first appointment to his post-treatment follow-up testing—using time-driven activity-based costing. For the ...

prostate cancer

ASTRO 2015: The Addition of 24 Months of Daily Antiandrogen Therapy Improves Overall Survival Following Recurrence After a Radical Prostatectomy

Prostate cancer patients who face recurrence after radical prostatectomy have better overall survival rates with a combination of salvage radiation therapy and 24 months of antiandrogen therapy than with radiation therapy alone, according to research (Abstract LBA5) presented by Shipley et al on...

prostate cancer

ASTRO 2015: A Shorter Radiation Therapy Schedule Can Be as Effective as a Conventional Schedule for Men With Low-Risk Prostate Cancer

Hypofractionated radiation therapy results in similar rates of cure and side effects compared to a longer treatment schedule for some men with low-risk prostate cancer, according to research (Abstract LBA6) presented by Lee et al October 19, 2015, at the American Society for Radiation Oncology...

prostate cancer
issues in oncology
issues in oncology

ASTRO 2015: Genomic Classifier Appears to Predict Metastasis in Patients With Prostate Cancer Following Prostatectomy

For men with prostate cancer who have had a prostatectomy and salvage radiation therapy, analyzing their tumor genome provides clues as to whether their cancer will metastasize, thereby enabling clinicians to better personalize treatment options, according to research presented by Den et al...

prostate cancer
issues in oncology

ASTRO 2015: Hypofractionated Radiation Therapy May Be an Acceptable Treatment for Some Patients With Localized Prostate Cancer

Long-term patient-reported outcomes indicate that for some men with localized prostate cancer, hypofractionated intensity-modulated radiation therapy (IMRT) may be a reasonable treatment option and result in similar quality-of-life outcomes, compared to conventional radiation therapy, according to...

prostate cancer

ASTRO 2015: Androgen-Deprivation Therapy for 2 Years After Radiotherapy Improves Disease-Free Survival in Patients With Advanced Prostate Cancer

A long-term follow-up of RTOG 9202 indicated that for patients with locally advanced prostate cancer, an additional 24 months of long-term androgen-deprivation therapy after radiation therapy plus short-term androgen-deprivation therapy improved disease-free survival by 60%, compared to patients...

prostate cancer
supportive care

Similar Pain Outcome With Ibandronate vs Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer

In a UK phase III noninferiority trial reported in the Journal of the National Cancer Institute, Hoskin et al found similar effects of single-dose ibandronate and single-dose radiotherapy on localized metastatic bone pain in patients with prostate cancer. Study Details In the open-label trial,...

prostate cancer
issues in oncology
palliative care

Aggressive End-of-Life Care More Frequent Among Black Than White Men With End-Stage Prostate Cancer

A study to examine racial disparities in end-of-life care among black and white patients dying of prostate cancer found that “significant racial disparities in end-of-life care" do exist. “Although diagnostic and therapeutic interventions are less frequent in black patients with...

prostate cancer
issues in oncology

Postprostatectomy Radiation Therapy Yields Low Toxicity and Favorable Patient-Reported Quality of Life

A prospective study of guideline-based, postoperative, image-guided intensity-modulated radiation therapy in patients with prostate cancer found low toxicity profiles and favorable patient-reported quality of life following treatment, with researchers concluding that toxicity and health-related...

prostate cancer

Active Surveillance Program Improves Intermediate/Longer-Term Outcomes in Favorable-Risk Prostate Cancer

As reported in the Journal of Clinical Oncology by Tosoian et al, a prospective active surveillance program resulted in good intermediate/longer-term outcomes in men with favorable-risk prostate cancer. Study Details The program included 1,298 men with very-low-risk or low-risk disease enrolled...

solid tumors
prostate cancer

Decreased Mortality for Men With Unfavorable-Risk Prostate Cancer and Moderate or Severe Comorbidities Treated With Radiotherapy Alone

Men with unfavorable-risk prostate cancer and moderate or severe comorbidities had significantly decreased overall and cardiac mortality when treated with radiotherapy alone vs radiotherapy and androgen-deprivation therapy, according to a study described in a research letter in JAMA. In the letter, ...

prostate cancer

Addition of Docetaxel to Androgen-Deprivation Therapy Improves Survival in Metastatic Prostate Cancer

In the phase III E3805 trial reported in The New England Journal of Medicine, Sweeney et al found that chemohormonal therapy with docetaxel plus androgen-deprivation therapy produced a significant 13.6-month increase in median overall survival vs androgen-deprivation therapy alone in men with...

breast cancer
prostate cancer

Packaging Paclitaxel in Nanoparticles May Increase Drug Efficacy in Preclinical Models

Duke University researchers found that packaging the widely used cancer drug paclitaxel into nanoparticles more than doubled the drug’s effectiveness in destroying tumors in preclinical models. Their findings were published by Bhattacharyya et al in Nature Communications. Paclitaxel has been ...

issues in oncology
prostate cancer

Biomarker Signature May Predict Aggressive Disease in African American Men With Prostate Cancer

In a study reported in Journal of Clinical Oncology, Yamoah et al identified a biomarker signature that may predict aggressive disease in African American men with prostate cancer. Study Details In the study, distribution of mRNA expression levels of 20 biomarkers associated with prostate cancer...

lung cancer
prostate cancer
issues in oncology

Long Telomere Length Associated With Increased Lung Cancer Risk

A large-scale genetic study of the links between telomere length and risk for five common cancers found that long telomeres are associated with an increased risk of lung adenocarcinoma. No significant associations between telomere length and other cancer types or subtypes were observed. The study,...

solid tumors
pancreatic cancer
prostate cancer
bladder cancer

Analysis Suggests Use of Pioglitazone for Diabetes May Increase Risk of Prostate and Pancreatic Cancers But Not Bladder Cancer

Available data suggest an increased risk of bladder cancer with pioglitazone treatment for diabetes. In an analysis of Kaiser Permanente Northern California data reported in JAMA, Lewis et al found no significantly increased risk of bladder cancer in patients with diabetes ever using pioglitazone....

Advertisement

Advertisement



Advertisement